Parkinson's Disease Clinical Trial
— HH4POfficial title:
Home-based High-intensity Interval Training for People With Parkinson's: The HIIT-Home4Parkinson's Randomised Controlled Feasibility Study
Verified date | May 2024 |
Source | University of Plymouth |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project aims to investigate the practicality and utility of home-based high-intensity interval training (HIIT) by undertaking a previously developed, novel home-based HIIT intervention for people with Parkinson's (PwP).
Status | Completed |
Enrollment | 13 |
Est. completion date | May 1, 2024 |
Est. primary completion date | April 25, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion criteria: - Diagnosed with Parkinson's disease - Aged 18 years or older (No upper limit) - Hoehn and Yahr stages 1-3 (Mild to moderate disease severity) - Capacity to consent under the Mental Capacity Act 2005, and able to follow an exercise programme - Based at home with enough space to perform an exercise programme - Willing and able to travel to intervention assessments - Access to a computer, Smart Phone, or tablet and to the internet. Exclusion criteria: - Other concurrent neurological condition - Co-morbidities that would prevent / be exacerbated by high-intensity exercise such as forms of cardiovascular disease - Advised to not participate following medical consultation - Participation in a contemporaneous interventional study |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals Plymouth NHS Trust | Plymouth | Devon |
Lead Sponsor | Collaborator |
---|---|
University of Plymouth |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Total weekly habitual physical activity | Weekly physical activity (minutes) measured with accelerometer, self administered | 1 week prior to start of exercise programme after baseline assessments | |
Other | Total weekly habitual physical activity | Weekly physical activity (minutes) measured with accelerometer, self administered | During week 7 of the exercise programme | |
Other | Maximum heart rate | Beats per minute, to be measured during VO2max assessment | 1 week before first exercise session | |
Other | Height | Height (centimetres) with stadiometer | 1 week before first exercise session | |
Other | Weight | Weight (kilograms) with calibrated digital scales | 1 week before first exercise session | |
Other | Lifestyle data questionnaire | 10-item basic lifestyle data bespoke questionnaire | 1 week before first exercise session | |
Other | Health screening questionnaire | Screening for health issues that may prevent participation | 1 week before first exercise session at baseline assessments | |
Primary | Programme completion | Number of weeks of exercise programme completed, self administered | Through study completion, an average of 12 weeks | |
Primary | Programme adherence | Number of exercise sessions completed in full, self administered | Through study completion, an average of 12 weeks | |
Primary | Change from baseline brain derived neurotrophic factor (BDNF) | Blood sample: Brain-derived neurotrophic factor (pg/ml) | 1 week before first exercise session and 1 day after last session. | |
Primary | Change from baseline Relative VO2max | Maximal oxygen uptake (ml/min/kg) incremental exercise test | 1 week before first exercise session and 1 day after last session. | |
Secondary | Adverse effects and events | Adverse effects and events related to exercise sessions, self administered | Through study completion, an average of 12 weeks | |
Secondary | Change from baseline 30 second sit to stand test | Number of times standing in 30 seconds | 1 week before first exercise session and 1 day after last session. | |
Secondary | Oxford Participation Activities Questionnaire | Participant administered lifestyle questionnaire | 1 week before first exercise session and 1 day after last session | |
Secondary | Change from baseline Movement Disorder Society Unified Parkinson's Disease Rating Scale part 3 | Motor examination, minimum score 0, maximum score 76, higher scores indicate increased disease severity | 1 week before first exercise session and 1 day after last session. | |
Secondary | Exercise intensity | Achieved exercise intensity (% of maximum heart rate), self administered | Through study completion, an average of 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 | |
Terminated |
NCT02924194 -
Deep Brain Stimulation of the nbM to Treat Mild Cognitive Impairment in Parkinson's Disease
|
N/A |